David Scott has a wealth of experience in the IT industry, with roles ranging from Head of IT to Program Manager to Enterprise IT Architect. David has worked with various companies such as Zurich Insurance, Tata Consultancy Services, and Swiss Re, where David was responsible for designing and implementing IT services, managing global IT operations, and creating support organizations and processes. David's expertise lies in IT service management, operational support processes, program management, and transitioning and transforming IT services. With a strong background in managing service centers, negotiating contracts, and ensuring compliance with regulatory frameworks, David has proven himself to be a valuable asset in the field of IT.
This person is not in any teams
This person is not in any offices
Institute of Molecular and Clinical Ophthalmology Basel (IOB)
At the Institute of Molecular and Clinical Ophthalmology Basel (IOB), basic researchers and clinicians work hand in hand to advance the understanding of vision, its diseases and to develop new therapies for vision loss. The institute is constituted as a foundation. IOB started operations in 2018. At IOB, we accelerate the conversion of basic research into innovative treatments which change the field of ophthalmic therapy. Interdisciplinary teams of researchers and clinicians work hand in hand. These problem-solvers and innovators have in-depth knowledge of unmet medical needs, and daily exposure to patients. Together, they improve the understanding of vision, and of the cells involved in eye disease. In this highly collaborative environment, IOB turns discoveries and technologies into clinical benefits for patients with blinding conditions. We help advance the practice of ophthalmic disease based on the genetic, structural and functional understanding of the cell types and their interactions within the human eye. At the Institute of Molecular and Clinical Ophthalmology Basel (IOB), basic researchers and clinicians work hand in hand to advance the understanding of eye diseases and to develop new therapies for vision loss.